Vinva Investment Management Ltd Takes $604,000 Position in DexCom, Inc. $DXCM

Vinva Investment Management Ltd acquired a new position in DexCom, Inc. (NASDAQ:DXCM) during the second quarter, HoldingsChannel.com reports. The fund acquired 6,994 shares of the medical device company’s stock, valued at approximately $604,000.

A number of other hedge funds have also added to or reduced their stakes in the business. Nuveen LLC acquired a new stake in DexCom in the 1st quarter valued at $554,893,000. Massachusetts Financial Services Co. MA grew its holdings in shares of DexCom by 106.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after acquiring an additional 3,410,858 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after acquiring an additional 1,868,241 shares during the last quarter. DSM Capital Partners LLC increased its position in shares of DexCom by 252.1% in the second quarter. DSM Capital Partners LLC now owns 1,435,296 shares of the medical device company’s stock valued at $125,287,000 after acquiring an additional 1,027,633 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after acquiring an additional 994,300 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on DXCM. Morgan Stanley decreased their price target on DexCom from $89.00 to $63.00 and set an “equal weight” rating for the company in a research note on Monday, November 10th. Weiss Ratings reissued a “sell (d+)” rating on shares of DexCom in a report on Monday, November 24th. Truist Financial reissued a “buy” rating and issued a $82.00 target price (down from $94.00) on shares of DexCom in a research note on Monday, November 3rd. Oppenheimer downgraded shares of DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Finally, Royal Bank Of Canada cut their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and an average price target of $86.73.

DexCom Stock Up 1.5%

DXCM stock opened at $63.46 on Friday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The business’s 50 day simple moving average is $64.31 and its 200 day simple moving average is $75.83. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $24.75 billion, a PE ratio of 44.07, a PEG ratio of 1.43 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter last year, the firm posted $0.45 EPS. The company’s quarterly revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the sale, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. This trade represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total value of $58,766.84. Following the sale, the director owned 27,031 shares of the company’s stock, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 9,999 shares of company stock worth $619,391 in the last ninety days. Insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.